Osteonecrosis News and Research

RSS

Finnish study finds poor oral health increases jawbone necrosis risks in breast cancer patients

Antiresorptive drugs, which reduce bone breakdown, are an important part of treatment for breast cancer that has spread to the bones. However, their use can be associated with osteonecrosis of the jaw (MRONJ), a condition in which bone tissue in the jaw dies.

14 Oct 2026

Coral-inspired scaffold enhances bone repair by reprogramming immune cells

SONFH is one of the leading causes of non-traumatic osteonecrosis. Reported in up to 9%–40% of patients receiving prolonged or high-dose glucocorticoid therapy, the condition progressively weakens the femoral head and can eventually lead to joint collapse, making effective bone repair a major clinical challenge.

13 Aug 2026

$Reducing femoral fractures in total hip replacement with safer implant designs$

Reducing femoral fractures in total hip replacement with safer implant designs

As populations continue to age, total hip replacement (THR) is becoming an increasingly common surgical procedure.

28 Oct 2025

Bone medications and steroids linked to increased risk of jaw disease

Certain medications used in the treatment of bone conditions, particularly when combined with corticosteroids, may significantly increase the risk of a rare but serious jaw disease.

3 Jun 2025

Network pharmacology analysis reveals HXTL mechanism in treating postmenopausal osteoporosis

Huo Xue Tong Luo Capsule (HXTL) has been clinically used to treat osteonecrosis of the femoral head, osteoporosis, and other bone and joint diseases with promising effects.

24 Apr 2025

Study reveals a potential breakthrough in treating osteonecrosis of the femoral head

A recent study has uncovered a potential breakthrough in treating osteonecrosis of the femoral head (ONFH), a debilitating bone disease that causes severe pain and joint collapse.

15 Apr 2025

47th annual San Antonio Breast Cancer Symposium kicks off in December

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), is hosting the 47th annual San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center on Dec. 10-13.

9 Dec 2024

NIH funding supports investigation of skeletal stem cells in craniofacial bone disorders

Researchers at UTHealth Houston have been awarded an $8.1 million grant by the National Institutes of Health (NIH) to examine skeletal stem cells as potential drivers of craniofacial bone diseases and deformities.

10 Oct 2024

New guideline focuses on the timing of hip and knee arthroplasty

The American College of Rheumatology and the American Association of Hip and Knee Surgeons released a summary of its new guideline titled "the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients with Symptomatic Moderate to Severe Osteoarthritis or Osteonecrosis Who Have Failed Nonoperative Therapy."

14 Mar 2023

Unique technology uses ultrasound-responsive nanobubbles for treating osteoporosis

University of Central Florida researchers have created unique technology for treating osteoporosis that uses nanobubbles to deliver treatment to targeted areas of a person's body.

6 Dec 2022

Researchers are developing calculator that weighs risk and benefit of taking osteoporosis drugs

Osteoporosis is a major, worsening public health problem and bisphosphonates which help restore a healthier balance of bone production and resorption, have been a relatively inexpensive, successful treatment, particularly for those at highest risk for fractures.

16 Nov 2022

Landmark study finds how often cancer patients develop osteonecrosis of the jaw

A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute, part of the National Institutes of Health, has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.

17 Dec 2020

$Researchers examine the implications of bisphosphonate drug holidays on fracture risk$

Researchers examine the implications of bisphosphonate drug holidays on fracture risk

Bisphosphonates have been shown to reduce the risk of osteoporotic fractures. To avoid possible side effects of long-term therapy, many patients take a drug holiday after several years of bisphosphonate therapy.

29 Jul 2020

New tools for analyzing microbial communities

The June 2020 issue of Journal of Dental Research brings together a collection of the latest research on the oral microbiome.

22 May 2020

Steroid injections for osteoarthritis more may damage joints

Osteoarthritis (OA), also called degenerative joint disease, is the most common chronic condition of the joints. Since the disease is degenerative, it is the single most common cause of disability among older adults, with about 10 to 15 percent of all adults who are more than 60 years old have some degree of osteoarthritis, with more women affected than men.

15 Oct 2019

USC researchers report breakthrough to prevent osteonecrosis of the jaw

USC researchers and collaborators report a breakthrough to prevent damage to the jaw, a side effect suffered by some people undergoing treatment for cancer or osteoporosis.

11 Apr 2019

Benefits of osteoporosis treatment in postmenopausal women outweigh the perceived risks

The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La.

25 Mar 2019

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

Pfizer Inc. and Eli Lilly and Company today announced that a 16-week Phase 3 study in patients with osteoarthritis pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints.

19 Jul 2018

New technique allows researchers to create large scale, personalized bone grafts

Scientists from the New York Stem Cell Foundation Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering.

18 Jul 2018